NeoGenomics: Q1 Earnings Snapshot

NeoGenomics reported a $17.1 million first quarter loss Tuesday, or 13 cents per share, but posted adjusted earnings of 1 cent a share. The Fort Myers-based operator of cancer-focused testing labs topped Wall Street targets: analysts surveyed by Zacks had expected breakeven, and revenue reached $186.7 million, above the $184.4 million forecast. The company guided full-year revenue to $797 million to $803 million.